A Change of Heart

Millions of patients experience heart attacks every year and the healthcare burden of heart failure continues to increase

FDY-5301 (a program in Phase 3) is being developed to protect patients from the life-changing impact of myocardial infarctions by targeting ischemia-reperfusion injury (IRI) to reduce cardiac damage and heart failure.

Picture of Dr. Mark Roth of the Fred Hutchinson Cancer Center — **Founded by Dr. Mark Roth** of the Fred Hutchinson Cancer Center

Our origins are in innovation

We’ve harnessed the unique properties of iodide through our investigational product: FDY-5301

This easy-to-administer product has been shown in preclinical models to neutralize deleterious hydrogen peroxide produced during ischemia-reperfusion injury, resulting in reduced tissue damage, inflammation, and infarct size.

ABOUT US

OUR MISSION:

Solving the reperfusion problem

Investigating sodium iodide as a novel approach for addressing ischemia-reperfusion injury (IRI)

intended to complement percutaneous coronary intervention (PCI) in the management of ST-elevation myocardial infarction (STEMI)

ABOUT FDY-5301

Our Pipeline

Learn about our development programs targeting unmet medical needs in acute conditions such as myocardial infarction and in chronic diseases such as cancer.

Learn more

Our Phase 3
clinical trial

FDY-5301 is currently being evaluated in a Phase 3 clinical trial (Iocyte AMI-3) to assess its potential to reduce heart failure and cardiovascular death among patients suffering from an anterior STEMI

A doctor and patient having a discussion

Learn more about Iocyte AMI-3 and see the promising results from Iocyte AMI, our completed Phase 2 clinical trial.

Clinical Trials

Recent News

Faraday Pharmaceuticals® Involved in Important Publication Exploring Iodine Redistribution During Trauma, Sepsis, and Hibernation and see the encouraging results from Iocyte AMI, our completed Phase 2 clinical trial for FDY-5301. READ MORE >